



UNIVERSITY OF
TORONTO

MUNK
SCHOOL
OF
GLOBAL
AFFAIRS

Join the Global Conversation

G7 Research Group

The
G7 Research Group
at the Munk School of Global Affairs at Trinity College in the University of Toronto
presents the

2015 Schloss Elmau G7 Summit Interim Compliance Report

9 June 2015 to 20 February 2016

Prepared by
Michael Humeniuk, Jerome Newton, Christian Medeiros and Kaleem Hawa
with Caroline Bracht
G7 Research Group, University of Toronto

30 March 2016

www.g7.utoronto.ca
g8@utoronto.ca
[@g7_rg](#) and [@g8rg](#)

“We have meanwhile set up a process and there are also independent institutions monitoring which objectives of our G7 meetings we actually achieve. When it comes to these goals we have a compliance rate of about 80%, according to the University of Toronto. Germany, with its 87%, comes off pretty well. That means that next year too, under the Japanese G7 presidency, we are going to check where we stand in comparison to what we have discussed with each other now. So a lot of what we have resolved to do here together is something that we are going to have to work very hard at over the next few months. But I think that it has become apparent that we, as the G7, want to assume responsibility far beyond the prosperity in our own countries. That’s why today’s outreach meetings, that is the meetings with our guests, were also of great importance.”

Chancellor Angela Merkel, Schloss Elmau, June 8, 2015

Contents

Preface	3
Executive Summary	5
Table A: 2015 Priority Commitments Selected for Assessment.....	6
Table B: 2015 Interim G7 Schloss Elmau Compliance Scores.....	7
Table C: 2015 Interim G7 Schloss Elmau Compliance Scores by Country.....	8
Table D: 2015 Interim G7 Schloss Elmau Compliance Scores by Commitment	8
1. Macroeconomic Policy: Foster Growth	9
2. Infrastructure: Infrastructure Investment.....	17
3. Climate Change: Growth Agenda	24
4. Financial Regulation: Tax Agenda.....	33
5. Nonproliferation: Arms Trade	40
6. Regional Security: Ukraine.....	46
7. Regional Security: Maritime.....	54
8. Human Rights: Migrants	63
9. Terrorism: Terrorists' Assets.....	72
10. Health: Coordinated Rapid Deployment	81
11. Health: National Action Plans	91
12. Health: Vaccines	99
13. Climate Change: Low-Carbon Strategies.....	106
14. Climate Change: Copenhagen Accord	117
15. Climate Change: Vulnerable Countries.....	125
16. Energy: Liberalizing Systems	136
17. Food and Agriculture: Voluntary Guidelines on the Responsible Governance.....	151

12. Health: Vaccines

“We will stimulate ... research focused on faster and targeted development of easily usable and affordable ... vaccines.”

G7 Schloss Elmau Summit Declaration

Assessment

	Lack of Compliance	Work in Progress	Full Compliance
Canada	-1		
France			+1
Germany			+1
Italy		0	
Japan			+1
United Kingdom			+1
United States			+1
European Union			+1
Average	+0.63		

Background

At the G7 Schloss Elmau Summit on 8 June 2015, the Leaders’ Declaration recognized “the highest attainable standard of health” as a “fundamental human right.”⁵⁶³ The development of easily usable and affordable vaccines is considered foundational to improving outcomes for two key aspects of human and veterinary health: antimicrobial resistance and neglected tropical diseases (NTDs).

Antimicrobial resistance has previously been a focus for the World Health Organization (WHO) through its Global Vaccine Action Plan issued in 2012, and the Global Action Plan on Antimicrobial Resistance announced in 2015. The former aimed to extend vital immunizations to the world’s population by 2020, while the latter focused on mitigating and responding to antibiotic resistance.⁵⁶⁴ International concern for this issue has been widespread: on 17 March 2015, the One Health International Congress highlighted research concerning “medical vs. veterinary drivers” for antibiotic resistance.⁵⁶⁵ WHO also pioneered a World Antibiotic Awareness Week, which began on 16 November 2015.⁵⁶⁶

On the issue of neglected tropical diseases, several actions have already been taken. The Global Fund mobilizes nearly USD4 billion each year towards ending AIDS, malaria and tuberculosis, with the development of affordable vaccines serving as a major aspect of these efforts.⁵⁶⁷ Additionally, the Global Strategy for Women’s, Children’s and Adolescent’s Health and the “Every Woman, Every Child” initiative aim to collaborate with the GAVI Alliance to achieve the goals of the Global Vaccine Action Plan, with the specific intention of improving maternal and child health outcomes through routine immunization.^{568,569}

⁵⁶³ Leaders’ Declaration: G7 Elmau Summit, 8 June 2015. Access Date: 31 December 2015. <http://www.g8.utoronto.ca/summit/2015elmau/2015-G7-declaration-en.html>

⁵⁶⁴ World Health Assembly addresses antimicrobial resistance, immunization gaps and malnutrition, World Health Organization (Geneva) 2015, Date of Access: Dec 31 2015. <http://www.who.int/mediacentre/news/releases/2015/wha-25-may-2015/en/>

⁵⁶⁵ 3rd International One Health Conference (Amsterdam) 2015, Date of Access: Jan 1 2016. <http://members.iohc2015.com/>

⁵⁶⁶ World Antibiotic Awareness Week, World Health Organization (Geneva) 2015, Date of Access: Jan 1 2016. <http://www.who.int/drugresistance/en/>

⁵⁶⁷ The Global Fund (Online) 2015, Date of Access: Jan 1 2016. <http://www.theglobalfund.org/en/>

⁵⁶⁸ Decade of Vaccines Collaboration, Every Woman, Every Child (Online) 2015, Date of Access: Jan 1 2016.

<http://www.everywomaneverychild.org/commitments/all-commitments/decade-of-vaccines-collaboration>

⁵⁶⁹ The Global Strategy for Women’s, Children’s, and Adolescents’ Health, Every Woman, Every Child (Italy) 2015, Date of Access: Jan 1 2016. <http://who.int/life-course/partners/global-strategy/globalstrategyreport2016-2030-lowres.pdf>

Commitment Features

The commitment to develop easily usable and affordable vaccines is part of a broader aim to improve health systems. In order to effectively reduce antimicrobial resistance, the Leaders' Declaration identifies the One Health approach to be optimal. The commitment stresses the importance of creating an integrated national action plan to lower infection rates by devoting resources towards new antibiotic and vaccine development.⁵⁷⁰

In terms of neglected tropical diseases, the commitment emphasizes “coordinating research and development efforts” towards “prevention, control, and treatment”; investing in accessible vaccines is a crucial aspect of disease prevention and control efforts for diseases such as AIDS, tuberculosis and malaria.⁵⁷¹

Members will be evaluated based upon their work to improve prior commitments and develop new projects targeted towards improving the quality and access to healthcare systems via investment into easily usable and affordable vaccines. These projects should focus on combatting antibiotic resistance or the improvement of health outcomes for NTDs. Examples include committing to increase the vaccination rate for an NTD, or investing in research and development for vaccines which could lower the need for antibiotics.

To achieve full compliance, members must show concrete action taken to improve healthcare systems, either nationally or internationally, using vaccines as a mechanism to combat antibiotic resistance or advance health outcomes for NTDs.

Scoring Guidelines

-1	Member does not take actions to develop affordable and easily usable vaccines.
0	Member takes actions to improve some aspect of vaccine use BUT does not tailor these actions towards antimicrobial resistance or neglected tropical diseases.
+1	Member takes actions to develop affordable and easily usable vaccines, including those used to lower instances of antibiotic use, and those used for NTDs.

Lead Analyst: Sarah Harrison

Canada: -1

Canada has not complied with its commitment to develop easily usable and affordable vaccines, both towards combatting antimicrobial resistance and addressing neglected tropical diseases.

Although in November 2014 and March 2015 the Government of Canada laid out a comprehensive federal framework for addressing antimicrobial resistance and vaccine development, it has not made concrete, publicly published progress in building upon this framework with specific programs since the June 2015 Elmau Summit.⁵⁷² Therefore, Canada has been awarded a score of -1.

Analyst: Aceel Hawa

France: +1

France has fully complied with the commitment to develop affordable and easily usable vaccines, including those used to lower instances of antibiotic use and those used for neglected tropical diseases.

On 23 September 2015, Marisol Touraine, French Minister of Social Affairs, Health and Women's Rights, announced that action would be undertaken to reduce the deaths of citizens to a spread of antibiotic resistant germ. Specific goals included a “25% reduction in the overall consumption of antibiotics and lowering

⁵⁷⁰ Leaders' Declaration: G7 Elmau Summit. 8 June 2015. Access Date: 14 January 2016.

<http://www.g8.utoronto.ca/summit/2015elmau/2015-G7-declaration-en.html>

⁵⁷¹ Leaders' Declaration: G7 Elmau Summit. 8 June 2015. Access Date: 14 January 2016.

<http://www.g8.utoronto.ca/summit/2015elmau/2015-G7-declaration-en.html>

⁵⁷² Antimicrobial Resistance and Use in Canada: A Federal Framework for Action (Online) 2015, Date of Access: Jan 28 2016.

<http://healthycanadians.gc.ca/drugs-products-medicaments-produits/buying-using-achat-utilisation/antibiotic-resistance-antibiotique/antimicrobial-framework-cadre-antimicrobiens-eng.php>

mortality related to antibiotic resistance below the 10 000 deaths per year threshold by 2017.”⁵⁷³ These goals were additional to a structured plan centred on four pillars, which are providing national steering actions against antimicrobial resistance (AMR), encourage research and innovation, allowing civil society to seize the issue by initiating community outreach and communication campaigns, and defending the recognition of a special status for antibiotics, to promote research of these drugs and facilitating access to new drugs market.

In addition, the minister advocated at the European Commission and the October G7 health ministers’ meeting on “the need for international coordination of initiatives taken by each country in this field.”⁵⁷⁴

On 17 November 2015 in Paris, the Joint Programming Initiative on Antimicrobial Resistance and the French Ministry of Health organized an intergovernmental workshop on AMR. Invited to the workshop were representatives from ministries, agencies, and funding bodies that gathered to understand the remit of ministries and agencies toward AMR and discuss ways to add value to new and existing programs of work through cooperation and coordination within and between countries.⁵⁷⁵

France has fully complied with its commitment to take action in the development of affordable and easily usable vaccines. Thus, France is awarded a score of +1.

Analyst: Michael Warchol

Germany: +1

Germany has fully complied with its commitment to develop more accessible and easily usable vaccines, with an emphasis on the “prevention, control, and treatment” of neglected tropical diseases and antimicrobial resistance (AMR).⁵⁷⁶

In November 2015, to ensure the continued progress in prevention and treatment of various neglected tropical diseases, Germany announced a 2016 G7 workshop on neglected tropical diseases. The focus of this workshop is to increase partnership between G7 members that are working together to combat such diseases in developing countries, while further defining what steps they actually need to take to help countries in need.⁵⁷⁷

On 25 September 2015, German Chancellor Angela Merkel, along with Ghana’s President John Dramani and Norway’s Prime Minister Erna Solberg, announced their development of an initiative aimed at preparing countries for and preventing global health crises.⁵⁷⁸ Part of this initiative also involved work with GAVI, the Vaccine Alliance, to ensure the creation of more accessible and affordable preventive vaccines. The three

⁵⁷³ Fight against antimicrobial resistance: Marisol Touraine sounds full mobilization of public authorities, Minister of Social Affairs Health and Women’s Rights September 23 2015. Date of Access: February 3 2016. <http://social-sante.gouv.fr/actualites/presse/communiqués-de-presse/article/lutte-contre-l-antibioresistance-marisol-touraine-sonne-la-mobilisation>

⁵⁷⁴ Fight against antimicrobial resistance: Marisol Touraine sounds full mobilization of public authorities, Minister of Social Affairs Health and Women’s Rights September 23 2015. Date of Access: February 3 2016. <http://social-sante.gouv.fr/actualites/presse/communiqués-de-presse/article/lutte-contre-l-antibioresistance-marisol-touraine-sonne-la-mobilisation>

⁵⁷⁵ JPIAMR and French Ministry of Health to host collaborative talks between European ministries agencies and funding bodies in the field of AMR, Joint Programming Initiative on Antimicrobial Resistance September 10 2015. Date Accessed: February 3 2016. <http://www.jpiaamr.eu/jpiaamr-and-french-ministry-of-health-to-host-collaborative-talks-between-european-ministries-agencies-and-funding-bodies-in-the-field-of-amr/>

⁵⁷⁶ Leaders’ Declaration: G7 Elmau Summit. 8 June 2015. Access Date: 14 January 2016. <http://www.g8.utoronto.ca/summit/2015elmau/2015-G7-declaration-en.html>

⁵⁷⁷ Final Report by the Federal Government on the G7 Presidency 2015, Press and Information Office of the Federal Government (Berlin, Germany) 15 December 2015, Date of Access: 28 Jan 2016, p. 29.

https://www.bundesregierung.de/Content/EN/_Anlagen/G7/2016-01-20-g7-abschluss-eng_en.pdf?__blob=publicationFile&v=3

⁵⁷⁸ Joint Press Release from Chancellor Angel Merkel of Germany, Prime Minister Erna Soldber of Norway, and President John Dramani Maham, Press and Information Office of the Federal Government (New York, USA) 25 September 2015, Date of Access: 28 Jan 2016, https://www.bundesregierung.de/Content/EN/Pressemitteilungen/BPA/2015/2015-09-25-merkel-solberg-mahama_en.html

hosted an event on the importance of strong healthcare systems that are prepared for a crisis, titled Securing a Healthy Future: Resilient Health Systems to Fight Epidemics and Ensure Healthy Lives. This was held during the United Nations Summit on the 2030 Agenda for Sustainable Development in New York. Chancellor Merkel announced a new roadmap she is launching called Healthy Systems — Healthy Lives, in order to further explore and discuss possible solutions.⁵⁷⁹

Overall, Germany has complied with its commitment to support research and funding for vaccines, with an emphasis on neglected tropical diseases. In 2015, it has demonstrated this by funding further important research and by forming projects and partnerships to ensure the long-term success of this commitment.

Therefore Germany has received a score of +1.

Analyst: Kendra Dempsey

Italy: 0

Italy has partially complied with the commitment to develop affordable and easily usable vaccines, including those used to lower antimicrobial resistance (AMR), and those used for neglected tropical diseases (NTDs).

On 11 September 2015, the Italian Ministry of Health released a statement on behalf of the Minister of Health Beatrice Lorenzin, reminding citizens to keep vaccinating themselves and their children.⁵⁸⁰ On 5 October 2015, the Italian Ministry of Health issued an announcement reminding citizens that vaccinations were available through the National Plan.⁵⁸¹ On 22 October 2015, the Minister of Health spoke to the house during question period and recommended that a new national plan for vaccination policy be implemented in order to offer expanded services to the public.⁵⁸² Institutional communication highlighting the risks of preventable diseases along with integrated information in educational content in school curricula was also recommended.⁵⁸³ On 17 November 2015, the Italian Ministry of Health issued a statement that 18 November is European Antibiotic Awareness Day, now a part of the newly formed World Health Organization initiative of World Antibiotic Awareness Week.⁵⁸⁴ All of these developments suggest an awareness of the importance of vaccination and a commitments to institutional knowledge dissemination in the space, but do not outright meet the commitment requirements that nations engage in financing or direct development of affordable vaccines, including those used to lower AMR or fight NTDs.

Italy has thus partially complied with its commitment on developing affordable and easily usable vaccines, and has been awarded a score of 0

Analyst: Michael Warchol

⁵⁷⁹ Joint Press Release from Chancellor Angel Merkel of Germany, Prime Minister Erna Solberg of Norway, and President John Dramani Mahama, Press and Information Office of the Federal Government (New York, USA) 25 September 2015, Date of Access: 28 Jan 2016, https://www.bundesregierung.de/Content/EN/Pressemitteliungen/BPA/2015/2015-09-25-merkel-mahama_en.html?nn=709674

⁵⁸⁰ Minister Lorenzin: I vaccinated my children, it is important, should not be afraid, Ministero della Salute September 11 2015. Date Accessed February 3 2016.

http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=2235

⁵⁸¹ Coperture vaccinali in età pediatrica, Ministero della Salute October 5 2015. Date Accessed February 3 2016.

http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=2267

⁵⁸² Lorenzin the House question time on vaccinations: “Approve early in the new plan, the resources you have and you can find”, Ministero della Salute October 22 2015. Date Accessed February 3 2016.

http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=2293

⁵⁸³ Lorenzin the House question time on vaccinations: “Approve early in the new plan, the resources you have and you can find”, Ministero della Salute October 22 2015. Date Accessed February 3 2016.

http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=2293

⁵⁸⁴ Antibiotic resistance the world's week a one-health approach, Ministero della Salute November 17 2015.

http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=2325

Japan: +1

Japan has fully complied with the commitment to develop affordable and easily usable vaccines, including those used to lower antimicrobial resistance (AMR) and those used for neglected tropical diseases (NTDs).

On 16 December 2015, Japan hosted the Global Fund's Fifth Replenishment Meeting on, where private sector organizations and non-profits met in Tokyo to make record-breaking commitments to support the fund through more than US\$37 million in pledges.⁵⁸⁵

Japan has also made significant contributions and pledges to the GAVI the Vaccine Alliance. Japan contributed USD17.6 million to GAVI for 2015 in support of health system recovery in Guinea, Liberia and Sierra Leone. The amount was doubled from the annual average in previous years and constitutes USD53.7 million in direct funding.⁵⁸⁶

The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) provides a collaborative platform to take the AMR combat from awareness to action by supporting research and facilitating its translation to industry and policy. On October 19, 2015, the JPIAMR voted in Japan, represented by the Japan Agency for Medical Research and Development as its newest partner member.⁵⁸⁷ The voting in of Japan is critical as it marks Japanese ambition to not only fulfill its G7 commitment but to excel while doing so.

In a declaration of "Japan's Vision for a Peaceful and Healthier World," Japanese Prime Minister Shinzo Abe, said "We reiterate the importance of the One Health approach in the fight against antimicrobial resistance, and of supporting countries to comply with the [World Health Organization] Global Action Plan on Antimicrobial Resistance, as confirmed at the G7 Elmau Summit."⁵⁸⁸ The Prime Minister's reiteration of a policy that Japan has been key in structuring reaffirms Japanese efforts towards completing its commitment.

Japan has fully complied with its commitment to take action in the development of affordable and easily usable vaccines. During 2015, Japan made multiple financial contributions to recognized health organizations focused on providing effective vaccines to eradicate NTDs. Japan has also made a large effort to lower its use of antibiotics.

Therefore Japan has received a score of +1.

Analyst: Michael Warchol

United Kingdom: +1

The United Kingdom has fully complied with its commitment to develop more accessible and easily usable vaccines, with an emphasis of the "prevention, control, and treatment" of neglected tropical diseases (NTDs) and antimicrobial resistance (AMR).⁵⁸⁹

In further efforts to combat neglected tropical diseases, the Chancellor of Exchequer announced the creation of the Ross Fund in November 2015.⁵⁹⁰ This fund has been created by the British government to specifically work with antimicrobial resistance, prevention of fast-spreading diseases that have the potential to cause

⁵⁸⁵ Private Sector Strongly Supports the Global Fund, The Global Fund 16 December 2015. Date of Access: February 27, 2016.

http://www.theglobalfund.org/en/news/2015-12-16_Private_Sector_Strongly_Supports_the_Global_Fund/

⁵⁸⁶ Donor Profile, GAVI- The Vaccine Alliance, September 30 2015. Date of Access: February 3 2016.

<http://www.gavi.org/funding/donor-profiles/japan/>

⁵⁸⁷ Japan joins as newest JPIAMR member, Joint Programming Initiative on Antimicrobial Resistance October 19 2015. Date Accessed: February 3 2016. <http://www.jpiaamr.eu/japan-joins-as-newest-jpiaamr-member/>

⁵⁸⁸ Japan's vision for a peaceful and healthier world, Ministry of Foreign Affairs of Japan December 12 2015. Date Accessed: February 3 2016. <http://www.mofa.go.jp/files/000117118.pdf>

⁵⁸⁹ Leaders' Declaration: G7 Elmau Summit, 8 June 2015. Access Date: 28 January 2016.

<http://www.g8.utoronto.ca/summit/2015elmau/2015-G7-declaration-en.html>

⁵⁹⁰ The Ross Fund – Combatting the world's most serious diseases, Department for International Development and Department of Health (England) 25 January 2016, Date of Access: 28 January 2016, <https://www.gov.uk/government/news/the-ross-fund-combatting-the-worlds-most-serious-diseases>

epidemics, and the prevention and treatment of a variety of neglected tropical diseases. An initial funding of GBP1 billion has been provided by the government. The specific details of this fund will be managed by both the Department of Health and the Department for International Development of the GBP1 billion, certain sums of money will go towards targeted issues.⁵⁹¹ For example, GBP90 million is specifically for work in the eradication of malaria.⁵⁹² Additionally, GBP100 million shall be used to further research into infectious diseases, including potential treatments. Finally, GBP115 million is being put towards the development of new diagnostic procedures as well as drugs and insecticides for malaria, tuberculosis and a variety of other infectious diseases.⁵⁹³

Overall, the United Kingdom has complied with its commitment to support research and funding for vaccines, with an emphasis on NTDs and AMR. In 2015, it has demonstrated its compliance through the funding of further important research, as well as by forming projects and partnerships to ensure the long-term success of this commitment. Therefore, the UK has received a score of +1.

Analyst: Kendra Dempsey

United States: +1

The United States has fully complied with its commitment to develop easily usable and affordable vaccines, with a focus on those aimed at preventing neglected tropical diseases (NTDs) and antimicrobial resistance (AMR).

The United States has cooperated with the international community on vaccine development in the context of NTDs and AMR. This longstanding partnership came into play again from 17 to 18 September 2015, during which the US-India Health Dialogue took place; both countries reaffirmed their commitment to dedicating Vaccine Action Program resources towards combatting AMR.⁵⁹⁴

The United States has been active on issues of antimicrobial resistance on a national level. On 18 December 2015, the US Congress approved an omnibus bill that allocated funding to reduce antibiotic resistance and support syringe service programs. The bill will provide USD160 million to the Centers for Disease Control and Prevention's (CDC) Antibiotic Resistance Solutions Initiative, which supports national outbreak detection, preventive control measures and overall improved antibiotic use. An additional USD3 million will go toward the CDC's National Healthcare Safety Network for increased surveillance of antibiotic use and resistance patterns.⁵⁹⁵

The US has fully complied with its commitment to support the development of easily usable and affordable vaccines, with an emphasis on NTDs and AMR. Throughout 2015, the US actively participated in international partnerships that have led to breakthroughs in vaccine research and development, as well as earmarking national funding towards future projects. Therefore the US has received a score of +1.

Analyst: Aceel Hawa

⁵⁹¹ Chancellor George Osborne and Bill Gates to join forces to end malaria, HM Treasury, Department for International Development, The Rt Hon Justine Greening MP and The Rt Hon George Osborne MP (England) 22 November 2015, Date of Access: 28 Jan 2016, <https://government/news/chancellor-george-osborne-and-bill-gates-to-join-forces-to-end-malaria>

⁵⁹² Chancellor George Osborne and Bill Gates to join forces to end malaria, HM Treasury, Department for International Development, The Rt Hon Justine Greening MP and The Rt Hon George Osborne MP (England) 22 November 2015, Date of Access: 28 Jan 2016,

⁵⁹³ Chancellor George Osborne and Bill Gates to join forces to end malaria, HM Treasury, Department for International Development, The Rt Hon Justine Greening MP and The Rt Hon George Osborne MP (England) 22 November 2015, Date of Access: 28 Jan 2016, <https://www.gov.uk/government/news/chancellor-george-osborne-and-bill-gates-to-join-forces-to-end-malaria>

⁵⁹⁴ U.S.-India Energy & Climate, Environment, Science & Technology, and Health Cooperation (Online) 2015, Date of Access: Feb 5 2016. <http://www.state.gov/r/pa/prs/ps/2015/09/247173.htm>

⁵⁹⁵ Increased congressional funding supports antibiotic resistance effort, syringe service programs (Online) 2015, Date of Access: Jan 28 2016. <http://www.healio.com/infectious-disease/practice-management/news/online/%7B6c390ea5-0000-48d7-afb7-f338f51cc80b%7D/increased-congressional-funding-supports-antibiotic-resistance-effort-syringe-service-programs>

European Union: +1

The European Union has fully complied with its commitment to develop more accessible and easily usable vaccines, with an emphasis on the “prevention, control, and treatment” of neglected tropical diseases (NTDs) and antimicrobial resistance (AMR).⁵⁹⁶

The EU has also created a project to fund vaccines for the hookworm virus, with this project benefitting India. The implementing organization is Academisch Medisch Centrum Bij de Universiteit van Amsterdam in the Netherlands, which has longstanding partnership between vaccine manufacturers in both India and Europe.⁵⁹⁷ The initial goal is to develop low-cost vaccines and antibiotics for the hookworm virus, with the goal of developing further vaccines for other NTDs. The total cost of this project is EUR418,000, with an EU contribution of EUR333,000. This project is expected to run until November 2018.

In December 2015, the EU gave a grant to for tropical disease research at the University of Glasgow.⁵⁹⁸ The fund will work to further development of vaccines for schistosomiasis, also known as snail fever.⁵⁹⁹ The 2015 European Research Council has provided EUR72 million to this research, with each grantee then receiving approximately EUR1.5 million each.⁶⁰⁰

Additionally, EUR1.62 billion has will be provided by the European Council by 2016 to support the Global Fund to Fight AIDS, Tuberculosis and Malaria.⁶⁰¹ Also EUR15 million is being pledged specifically for research into testing and preventive measures for diseases like HIV/AIDS.⁶⁰²

Although the details have not been fully ironed out, the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR), a partnership between the EU and the United States, held a meeting on 22 October 2015.⁶⁰³ The focus of this meeting, as well as future meetings, is to put together a five-year action plan for fighting AMR, by defining how antibiotics should be used, and how to prevent resistance to them in the future. Final results from these meetings are expected to be released soon.

Overall, the European Union has complied with its commitment to support research and funding for vaccines, with an emphasis on NTDs and AMR. In 2015, they have demonstrated their compliance through the funding of further important research, as well as by forming projects and partnerships to ensure the long-term success of this commitment. Therefore, the European Union has received a score of +1.

Analyst: Kendra Dempsey

⁵⁹⁶ Leaders’ Declaration: G7 Elmau Summit, 8 June 2015. Access Date: 28 January 2016.

<http://www.g8.utoronto.ca/summit/2015elmau/2015-G7-declaration-en.html>

⁵⁹⁷ EU-India research and innovation partnership on vaccine development for hookworm and other Neglected Tropical Diseases, International Cooperation and Building Partnerships for Change in Developing Countries, Date of Access: 28 Jan 2016, http://ec.europa.eu/europeaid/projects/eu-india-research-and-innovation-partnership-vaccine-development-hookworm-and-other_en

⁵⁹⁸ Glasgow grantee gets EU funding for work on a tropical disease, Representation in United Kingdom, 4 December 2015, Date of Access: 28 Jan 2016, http://ec.europa.eu/unitedkingdom/press/frontpage/2015/130_en.htm.

⁵⁹⁹ Glasgow grantee gets EU funding for work on a tropical disease, Representation in United Kingdom, 4 December 2015, Date of Access: 28 Jan 2016, http://ec.europa.eu/unitedkingdom/press/frontpage/2015/130_en.htm.

⁶⁰⁰ Glasgow grantee gets EU funding for work on a tropical disease, Representation in United Kingdom, 4 December 2015, Date of Access: 28 Jan 2016, http://ec.europa.eu/unitedkingdom/press/frontpage/2015/130_en.htm.

⁶⁰¹ World AIDS Day 2015: Joint Statement by HR/VP Mogherini and Commissioners Andriukaitis, Mimica and Moedas, European Commission (Brussels, Belgium), 30 November 2015, Date of Access: 6 Feb 2016 http://europa.eu/rapid/press-release_STATEMENT-15-6197_en.htm.

⁶⁰² World AIDS Day 2015: Joint Statement by HR/VP Mogherini and Commissioners Andriukaitis, Mimica and Moedas, European Commission (Brussels, Belgium), 30 November 2015, Date of Access: 6 Feb 2016 http://europa.eu/rapid/press-release_STATEMENT-15-6197_en.htm.

⁶⁰³ 2015 Meeting of the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) – “Let’s Keep Antibiotics Effective!” Employment, Social Policy, Health and Consumer Affairs (Luxembourg), 22 October 2015, Date of Access: 6 Feb 2016 <http://www.eu2015lu.eu/en/agenda/2015/10/22-conf-taftar/index.html>.